Pfizer Inc
Change company Symbol lookup
Select an option...
PFE Pfizer Inc
BRT BRT Apartments Corp
EYPT EyePoint Pharmaceuticals Inc
NKRKY Nokian Tyres plc
USEG US Energy Corp
RENO Renovare Environmental Inc
CRT Cross Timbers Royalty Trust
LUV Southwest Airlines Co
AVA Avista Corp
NJR New Jersey Resources Corp
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company offers therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator in development for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. The Company's medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness.

Closing Price
$52.31
Day's Change
-0.12 (-0.23%)
Bid
--
Ask
--
B/A Size
--
Day's High
52.37
Day's Low
51.25
Volume
(Light)
Volume:
16,143,272

10-day average volume:
22,369,252
16,143,272

PFE's position in the Pharmaceuticals industry

Industry PeersPFELLYMRKBMYPCRX

Summary

Company ProfilePfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical...
Eli Lilly and Company is a drug manufacturing company. The Company is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The...
Go to LLY summary
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through...
Go to MRK summary
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical...
Go to BMY summary
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company is engaged in advancing a pipeline of products across a range of therapeutic areas that include acute...
Go to PCRX summary
52-Week Change

VS. INDUSTRY
32.23%
40.49%
18.50%
15.44%
-3.55%
Market Cap

VS. INDUSTRY
$293.5B
$308.5B
$233.7B
$163.6B
$2.6B
Beta

VS. INDUSTRY
0.7
0.4
0.4
0.4
0.9
Dividend Yield

VS. INDUSTRY
3.06%
1.21%
2.99%
2.81%
--
P/E (TTM, GAAP)

VS. INDUSTRY
11.79x
48.19x
16.85x
27.28x
68.95x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$92.4B
$29.3B
$54.0B
$47.0B
$580.5M
Profit Margin

VS. INDUSTRY
27.56%
20.90%
25.78%
13.35%
6.62%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
27.43%
18.88%
28.17%
3.27%
--
Revenue Growth (TTM)

VS. INDUSTRY
100.43%
15.06%
28.96%
9.69%
31.04%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.